Journal
GUT
Volume 68, Issue 6, Pages 1065-1075Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2018-316408
Keywords
-
Categories
Funding
- Bayer HealthCare Pharmaceuticals
- Onyx, a wholly owned subsidiary of Amgen
- European Commission (EC)/Horizon 2020 Program (HEPCAR) [667273-2]
- US Department of Defense [CA150272P3]
- Asociacion Espanola Contra el Cancer (AECC)
- National Cancer Institute [P30-CA196521]
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute [SAF2016-76390]
- Generalitat de Catalunya/AGAUR [SGR-1162, SGR-1358]
- Instituto de Salud Carlos III (ISCIII) [PI14/00962]
- AECC
- AGAUR [SGR-605]
- WCR (AICR) [16-0026]
- Spanish Health Ministry (Plan Estrategico Nacional contra la Hepatitis C)
- ISCIII
- EC
- MINECO [BES-2014-068300]
- ISCIII-SEOM
- AGAUR
- Miguel Servet grant [ISCIIICP13/00160]
- Tisch Cancer Institute
- American Association for the Study of Liver Diseases Foundation (AASLDF)
Ask authors/readers for more resources
Objective Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/ local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic factors with B level of evidence. Design T umour tissue from 188 patients randomised to receive sorafenib (83) or placebo (105) in the STORM trial was collected. Analyses included gene expression profiling, targeted exome sequencing (19 known oncodrivers), immunohistochemistry (pERK, pVEGFR2, Ki67), fluorescence in situ hybridisation (VEGFA) and immunome. A gene signature capturing improved RFS in sorafenib-treated patients was generated. All 70 RFS events were recurrences, thus time to recurrence equalled RFS. Predictive and prognostic value was assessed using Cox regression models and interaction test. Results BIOSTORM recapitulates clinicopathological characteristics of STORM. None of the biomarkers tested (related to angiogenesis and proliferation) or previously proposed gene signatures, or mutations predicted sorafenib benefit or recurrence. A newly generated 146-gene signature identifying 30% of patients captured benefit to sorafenib in terms of RFS (p of interaction= 0.04). These sorafenib RFS responders were significantly enriched in CD4+ T, B and cytolytic natural killer cells, and lacked activated adaptive immune components. Hepatocytic pERK (HR= 2.41; p= 0.012) and microvascular invasion (HR= 2.09; p= 0.017) were independent prognostic factors. Conclusion I n BIOSTORM, only hepatocytic pERK and microvascular invasion predicted poor RFS. No mutation, gene amplification or previously proposed gene signatures predicted sorafenib benefit. A newly generated multigene signature associated with improved RFS on sorafenib warrants further validation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available